Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
Recruiting
18 years - 99 years
All
Phase
2
52 participants needed
1 Location
Brief description of study
This trial studies how well pevonedistat alone or in combination with chemotherapy (paclitaxel and carboplatin) works in treating patients with bile duct cancer of the liver. Pevonedistat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: liver cancer,cancer,Metastatic Cholangiocarcinoma
-
Age: 18 years - 99 years
-
Gender: All
Male or Female, Age 18 or older with histologically confirmed intrahepatic cholangiocarcinoma or biphasic hepatocellular carcinoma and cholangiocarcinom
Updated on
04 Aug 2024.
Study ID: 843850